1
|
Jaroch D, Guo J, LaPorte J, Parise R, Griffin D, Cox B, Beumer J, Arepally A, Katz S. Abstract No. 400 Comparison of pancreatic tissue uptake of oxaliplatin delivered by systemic circulation and by pancreatic retrograde venous infusion (PRVI). J Vasc Interv Radiol 2022. [DOI: 10.1016/j.jvir.2022.03.481] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
2
|
Selvaraj H, Damadarosamy K, Natarajan K, Rani KRV, Duraisamy K, Parise R, Dhanasekaran M, Deruiter J, Ren J, Thangavel S. Critical Clinical Evaluation of Covid-19 Patients with Tuberculosis in the Indian Sub-Continent. Curr Drug Saf 2022; 18:276-283. [PMID: 35593332 DOI: 10.2174/1574886317666220518092819] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2022] [Revised: 02/22/2022] [Accepted: 03/17/2022] [Indexed: 11/22/2022]
Abstract
BACKGROUND COVID-19 and tuberculosis (TB) are infectious diseases that predominantly affect the respiratory system with common symptoms such as cough, fever, and shortness of breath, making them dual burdens. METHODS This review will discuss the characteristics of the coexistence of TB and new infectious illnesses to provide a framework for addressing the current epidemic. Currently, there are no clear and significant data on COVID-19 infection in TB patients, they may not respond appropriately to drug therapy and may have worse treatment outcomes, especially if their TB treatment is interrupted. Due to emergence, measurements should be taken to minimize TB and COVID-19 transmission in communal settings and health care institutions were created. For both TB and COVID-19, accurate diagnostic testing and well-designed, and established therapeutic strategies are required for effective treatment. RESULTS Several health care organizations and networks have specimen transit methods that can be utilized to diagnose and monitor the etiology and progression of COVID 19 and perform contact tracing in developed and underdeveloped nations. Furthermore, patients and health care programs could benefit from increased use of digital health technology, which could improve communication, counseling, treatment, and information management, along with other capabilities to improve health care. CONCLUSIONS Patients with COVID-19 pulmonary/respiratory problems may seek treatment from respiratory physicians, pulmonologists, TB experts, and even primary health care workers. To have prophylactic and therapeutic strategies against COVID-19, TB patients should take the appropriate health care measures recommended by health care professionals/government officials and maintain their TB therapy as indicated.
Collapse
Affiliation(s)
| | | | | | | | - Kanagaraj Duraisamy
- Deputy Director of Medical Services, District TB Centre, Erode, Tamilnadu, India
| | | | | | - Jack Deruiter
- Department of Cardiology, Zhongshan Hospital Fudan University, Shanghai 200032, China
| | - Jun Ren
- Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA 98195 USA
| | | |
Collapse
|
3
|
Parise R, Deruiter J, Ren J, Govindarajulu M, Ramesh S, Nadar RM, Moore T, Dhanasekaran M. Impact of COVID-19 therapy on hyperglycemia. Diab Vasc Dis Res 2022; 19:14791641221095091. [PMID: 35695412 PMCID: PMC9194500 DOI: 10.1177/14791641221095091] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/03/2022] Open
Abstract
The goal of this study was to analyze the effect of COVID-19 drugs and biologicals on hyperglycemia. A literature search with key terms, such as "COVID-19 drugs and hyperglycemia" and "COVID-19 vaccines and hyperglycemia," was conducted using PubMed through September 2021. The CDC data were referenced for current COVID-19 profile and statistics. The NIH COVID-19 guidelines were referenced for updated treatment recommendations. Micromedex and UpToDate were used for drug and disease information. Current results suggested that corticosteroids (dexamethasone), remdesivir and antivirals (lopinavir and ritonavir) all have the potential to significantly raise blood glucose levels putting patients at elevated risk for severe complications. In contrary, hydroxychloroquine is associated with hypoglycemia, and tocilizumab decreases inflammation which is associated with improving glucose levels. Other anti-cytokine bioactive molecules are correlated with lower blood glucose in patients with and without diabetes mellitus. Ivermectin, used for mild COVID-19 disease, possesses the potential for lowering blood glucose. Covishield, Pfizer-BioNTech, and Moderna have all been associated with hyperglycemia after the first dose. Individualized /personalized patient care is required for diabetic mellitus patients with COVID-19 infection. Improper drug therapy aggravates hyperglycemic conditions and other comorbid conditions, leading to increased morbidity and mortality.
Collapse
Affiliation(s)
- Rachel Parise
- Department of Drug Discovery and Development, 15460Auburn University Harrison School of Pharmacy, Auburn, AL, USA
| | - Jack Deruiter
- Department of Drug Discovery and Development, 15460Auburn University Harrison School of Pharmacy, Auburn, AL, USA
| | - Jun Ren
- Department of Cardiology, 92323Zhongshan Hospital Fudan University, Shanghai, China
- Department of Laboratory Medicine and Pathology, 7284University of Washington, Seattle, WA, USA
| | - Manoj Govindarajulu
- Department of Drug Discovery and Development, 15460Auburn University Harrison School of Pharmacy, Auburn, AL, USA
| | - Sindhu Ramesh
- Department of Drug Discovery and Development, 15460Auburn University Harrison School of Pharmacy, Auburn, AL, USA
| | - Rishi M Nadar
- Department of Drug Discovery and Development, 15460Auburn University Harrison School of Pharmacy, Auburn, AL, USA
| | - Timothy Moore
- Department of Drug Discovery and Development, 15460Auburn University Harrison School of Pharmacy, Auburn, AL, USA
| | - Muralikrishnan Dhanasekaran
- Department of Drug Discovery and Development, 15460Auburn University Harrison School of Pharmacy, Auburn, AL, USA
- Muralikrishnan Dhanasekaran, Department of Drug Discovery and Development, Auburn University Harrison School of Pharmacy, 3306, Walker Building, Auburn, AL 36849, USA.
| |
Collapse
|
4
|
Cerrato M, Badellino S, Menegatti F, Bonavero I, Grossi C, Lo Zito B, Orlandi E, Gastino A, Cuffini E, Blasi L, Mantovani C, Parise R, Ricardi U, Levis M. PD-0672 Cardiac toxicity predicts mortality in NSCLC patients: interim analysis of the LUNG-HEART Study. Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)02919-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
5
|
Chiofalo V, Iorio G, Bonavero I, Parise R, Carlevato R, Bartoncini S, Richetto V, Ceci F, Grimaldi S, Dall’Armellina S, Deandreis D, Lillaz B, Oderda M, Gontero P, Guarneri A, Ricardi U. PO-1335 PSMA-PET impact on post-prostatectomy recurrencies multidisciplinary management: focus on RT. Radiother Oncol 2021. [DOI: 10.1016/s0167-8140(21)07786-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
6
|
Levis M, De Luca V, Bartoncini S, Orlandi E, Iorio G, Parise R, Palladino C, Cavallin C, Botto B, Giglioli F, Fiandra C, Ricardi U. OC-0459: Clinical outcomes in Hodgkin Lymphoma patients treated with IMRT-VMAT according to ISRT principles. Radiother Oncol 2020. [DOI: 10.1016/s0167-8140(21)00481-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
7
|
De Luca V, Bartoncini S, Iorio G, Parise R, Orlandi E, Cavallin C, Palladino C, Levis M, Ricardi U. PO-0920: Low dose radiation therapy (2 Gy x 2) in the treatment of Marginal Zone Lymphomas. Radiother Oncol 2020. [DOI: 10.1016/s0167-8140(21)00937-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
8
|
Orlandi E, De Luca V, Gallio E, Bartoncini S, Iorio G, Parise R, Cavallin C, Palladino C, Fiandra C, Levis M, Ricardi U. OC-0201: Hodgkin Lymphoma patients treated with IMRT: from dosimetric analysis to cardiovascular disease risk. Radiother Oncol 2020. [DOI: 10.1016/s0167-8140(21)00225-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
9
|
Levis M, Solidoro P, Bartoncini S, Gallio E, Giglioli F, De Luca V, Focaraccio L, Cavallin C, Iorio G, Parise R, Palladino C, Di Martino V, Furfaro G, Rovere G, Mattei A, Ragona R, Ricardi U. OC-0067 Continuous Positive Airway Pressure (CPAP): an innovative respiratory gating in lymphoma patients. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)30487-6] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
10
|
Parise R, Bartoncini S, Guarneri A, Deandreis D, Lillaz B, Solla S, Spinelli L, Nicolotti D, Pilati E, Bellò M, Passera R, Gontero P, Bisi G, Ricardi U. PO-0835 68GaPSMA11 PET/CT in prostate cancer patients with biochemical recurrence: PET positivity predictors. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)31255-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
11
|
De Luca V, Bartoncini S, Levis M, Gallio E, Cavallin C, Iorio G, Parise R, Palladino C, Giglioli F, Fiandra C, Ricardi U. PV-0365 Adoption of expansion margins to reduce the dose received by coronary arteries in lymphoma patients. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)30785-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|